Skip to content
EmergingResearch compoundReference only

BPAP

Experimental compound that boosts the dopamine signal of nerve cells; only early animal data, with a liver-damage warning sign.

NootropicDopaminergicNeuroprotectionDopamineNorepinephrineSerotonin

Pharmacology

ClassDopaminergic · Neuroprotection
Primary targetCatecholamine / serotonin activity enhancement (not release)
Targets2 receptor targets
EvidenceReference only
Affected systemsDopamineNorepinephrineSerotonin

Contents

DETAILED OVERVIEW

What is BPAP?

BPAP is an experimental compound designed to build on the nerve-protecting effect of the medicine selegiline. It is not approved as a medicine anywhere. So far there are only early, mostly lab and animal data, and it has not been proven in humans.

It works by strengthening only nerve activity that is already happening: with every nerve impulse it releases more dopamine, norepinephrine and serotonin, but it does not trigger release on its own, unlike amphetamines. In mouse cells it increased the production of substances that help nerve cells grow, and in animal models it showed antidepressant and pro-social effects. An animal study found a signal of liver damage, so long-term use is a serious safety concern. There is hardly any human safety data. It should be avoided in pregnancy, breastfeeding and liver disease; together with other drugs that act on dopamine or serotonin, the effect of serotonin or dopamine may become too strong.

Mechanism

CAE, presynaptic monoaminergic

Half-life

No human data

Legal status

Investigational, not approved

Receptor profile

  • Catecholamine / serotonin activityStrong
  • TAAR1Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Limited human safety data, effects are largely preclinical (animal) and anecdotal
  • Possible mild stimulation, restlessness or sleep disturbance due to enhanced catecholaminergic activity
  • Mood shifts, irritability or anxiety possible from monoaminergic modulation
  • Potential hepatotoxicity (liver strain) even at low doses, based on an animal study signal
  • Blood pressure or heart rate changes theoretically possible due to noradrenergic effect (no human data)
  • Unknown long-term safety profile, consequences of chronic use are not studied

Contraindications · 5

  • Avoid during pregnancy and breastfeeding, no safety data available
  • Avoid with existing liver disease or elevated liver enzymes due to the documented hepatotoxicity signal
  • Avoid combining with other monoaminergic agents (antidepressants, MAO inhibitors, stimulants) due to risk of serotonergic or catecholaminergic excess
  • Caution advised with cardiovascular disease or hypertension due to the noradrenergic effect
  • Unapproved, experimental-only compound, human dosing and safety standards are not established

Related Nootropics

Same therapeutic category

FAQ

FAQ

BPAP is an experimental compound designed as a successor to the well-known Selegiline, aiming to extend its neuroprotective properties further. Human data on it is essentially nonexistent, so it counts as a research-lab, experimental substance rather than an established or widely tested one.

Telegram

Have a question about BPAP?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC16H23NO
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.